» Articles » PMID: 38200091

Disruption of Lysosomal Proteolysis in Astrocytes Facilitates Midbrain Organoid Proteostasis Failure in an Early-onset Parkinson's Disease Model

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Jan 10
PMID 38200091
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulation of advanced glycation end products (AGEs) on biopolymers accompanies cellular aging and drives poorly understood disease processes. Here, we studied how AGEs contribute to development of early onset Parkinson's Disease (PD) caused by loss-of-function of DJ1, a protein deglycase. In induced pluripotent stem cell (iPSC)-derived midbrain organoid models deficient for DJ1 activity, we find that lysosomal proteolysis is impaired, causing AGEs to accumulate, α-synuclein (α-syn) phosphorylation to increase, and proteins to aggregate. We demonstrated these processes are at least partly driven by astrocytes, as DJ1 loss reduces their capacity to provide metabolic support and triggers acquisition of a pro-inflammatory phenotype. Consistently, in co-cultures, we find that DJ1-expressing astrocytes are able to reverse the proteolysis deficits of DJ1 knockout midbrain neurons. In conclusion, astrocytes' capacity to clear toxic damaged proteins is critical to preserve neuronal function and their dysfunction contributes to the neurodegeneration observed in a DJ1 loss-of-function PD model.

Citing Articles

Age-Related Neurodegenerative Diseases: A Stem Cell's Perspective.

Calvo B, Schembri-Wismayer P, Duran-Alonso M Cells. 2025; 14(5).

PMID: 40072076 PMC: 11898746. DOI: 10.3390/cells14050347.


Lysosomal acidification impairment in astrocyte-mediated neuroinflammation.

Zeng J, Indajang J, Pitt D, Lo C J Neuroinflammation. 2025; 22(1):72.

PMID: 40065324 PMC: 11892208. DOI: 10.1186/s12974-025-03410-w.


Two- and Three-Dimensional In Vitro Models of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Applications.

Solana-Manrique C, Sanchez-Perez A, Paricio N, Munoz-Descalzo S Int J Mol Sci. 2025; 26(2).

PMID: 39859333 PMC: 11766061. DOI: 10.3390/ijms26020620.


Cellular senescence in Alzheimer's disease: from physiology to pathology.

Zhu J, Wu C, Yang L Transl Neurodegener. 2024; 13(1):55.

PMID: 39568081 PMC: 11577763. DOI: 10.1186/s40035-024-00447-4.


Human midbrain organoids: a powerful tool for advanced Parkinson's disease modeling and therapy exploration.

Cui X, Li X, Zheng H, Su Y, Zhang S, Li M NPJ Parkinsons Dis. 2024; 10(1):189.

PMID: 39428415 PMC: 11491477. DOI: 10.1038/s41531-024-00799-8.


References
1.
Rad R, Li J, Mintseris J, OConnell J, Gygi S, Schweppe D . Improved Monoisotopic Mass Estimation for Deeper Proteome Coverage. J Proteome Res. 2020; 20(1):591-598. DOI: 10.1021/acs.jproteome.0c00563. View

2.
di Domenico A, Carola G, Calatayud C, Pons-Espinal M, Munoz J, Richaud-Patin Y . Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. Stem Cell Reports. 2019; 12(2):213-229. PMC: 6372974. DOI: 10.1016/j.stemcr.2018.12.011. View

3.
Sarrafha L, Parfitt G, Reyes R, Goldman C, Coccia E, Kareva T . High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells. STAR Protoc. 2021; 2(2):100463. PMC: 8086141. DOI: 10.1016/j.xpro.2021.100463. View

4.
Bandopadhyay R, Kingsbury A, Cookson M, Reid A, Evans I, Hope A . The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain. 2003; 127(Pt 2):420-30. DOI: 10.1093/brain/awh054. View

5.
Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View